By Colin Kellaher
OptimizeRx shares rose more than 10% on Monday after the provider of healthcare-technology solutions posted third-quarter results that topped Wall Street’s expectations and forecast full-year revenue that also topped analyst views.
Shares of the Waltham, Mass., company were recently trading at $9.55, up more than 12%.
OptimizeRx reported quarterly adjusted earnings of 9 cents a share amid an 8% rise in revenue to $16.3 million.
Analysts polled by FactSet, on average, were expecting a profit of 3 cents a share on revenue of $15.1 million.
OptimizeRx said it now expects revenue of $68 million to $70 million in 2023, ahead of the $61.9 million analysts had penciled in, and the company gave preliminary 2024 revenue guidance of at least $110 million.
Write to Colin Kellaher at [email protected]
Read the full article here